Oct 31, 2011 by Brian Orelli, PhD5 One-Drug Wonders Going for No. 2The second one counts as much as the first.
Oct 31, 2011 by Brian Orelli, PhDWhen Getting Beat Down Is No Big DealMerck has the bulk to take a beatdown.
Oct 28, 2011 by Brian Orelli, PhDInvest in Biotechs Going After Unmet NeedsVertex nails its launch of hepatitis C drug Incivek.
Oct 28, 2011 by Brian Orelli, PhDFocus on Profits, Biotech InvestorsElan is in the black and looking as healthy as ever.
Oct 28, 2011 by Brian Orelli, PhDThe Calm Before the Revenue Storm?Gilead's growth is decelerating, but it still has a few tricks up its sleeve.
Oct 27, 2011 by Brian Orelli, PhDDEFINE First, CONFIRM Second, See Shares Rise 60% ThirdBiogen CONFIRMs it has a new blockbuster drug.
Oct 26, 2011 by Brian Orelli, PhDDown 20%: Benylsta Not Ramping Fast EnoughBut it's how you finish that counts.
Oct 26, 2011 by Brian Orelli, PhDMomenta Stopped. Again.Oh, no -- an authorized generic gets launched.
Oct 25, 2011 by Brian Orelli, PhDAnemic Growth in All the Right PlacesAmgen's anemia drugs decline, but that's not its future anyway.
Oct 24, 2011 by Brian Orelli, PhDBiotech Blunder Turned 20% Overnight GainExelixis gets good data, even if it wasn't exactly what it was expecting.
Oct 20, 2011 by Brian Orelli, PhDMini J&J? I Guess NotAbbott decides taking the breakup pill is a better choice.
Oct 19, 2011 by Brian Orelli, PhDThis High-Tech Company Still Has the TouchIntuitive Surgical beats analysts' expectations. Again.
Oct 19, 2011 by Brian Orelli, PhDNot the Best Quarter, but...There's little reason to worry about Johnson & Johnson.
Oct 18, 2011 by Brian Orelli, PhDHow Not to Gain 75% of Your Company's Value OvernightSequenom finally launches its Down syndrome test.
Oct 6, 2011 by Brian Orelli, PhDData Published; Back to WaitingPhase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important.
Oct 5, 2011 by Brian Orelli, PhD1 Sure Sign of an FDA ApprovalThere are no guarantees in biotech, but a class 1 response is close.
Oct 5, 2011 by Brian Orelli, PhDPfizer's Selling, Not Buying, Pipeline Drugs?Perhaps it's for the best.
